Re: Thoughts on ZCC
in response to
by
posted on
Sep 06, 2021 12:00AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KOO - In addition to what tada stated, I believe ZEL has the IP so they could sell ZEL and keep the Royalty Preferreds in ZCC or they could shift some of the IP to ZCC and sell the rest within ZEL or start another entity and shift some IP to it and sell it and keep the remainder in ZEL within ZCC ar any other number of actions they want to make whatever deal the parties would want.